LLY

749.02

-1.17%↓

JNJ

149.13

-3.49%↓

UNH

309.25

-18.39%↓

ABBV

188.73

-1.26%↓

ABT

129.31

-1.88%↓

LLY

749.02

-1.17%↓

JNJ

149.13

-3.49%↓

UNH

309.25

-18.39%↓

ABBV

188.73

-1.26%↓

ABT

129.31

-1.88%↓

LLY

749.02

-1.17%↓

JNJ

149.13

-3.49%↓

UNH

309.25

-18.39%↓

ABBV

188.73

-1.26%↓

ABT

129.31

-1.88%↓

LLY

749.02

-1.17%↓

JNJ

149.13

-3.49%↓

UNH

309.25

-18.39%↓

ABBV

188.73

-1.26%↓

ABT

129.31

-1.88%↓

LLY

749.02

-1.17%↓

JNJ

149.13

-3.49%↓

UNH

309.25

-18.39%↓

ABBV

188.73

-1.26%↓

ABT

129.31

-1.88%↓

Search

Verve Therapeutics Inc

Abierto

4.12 -3.29

Resumen

Variación precio

24h

Actual

Mínimo

4.03

Máximo

4.36

Métricas clave

By Trading Economics

Ingresos

98K

-50M

Ventas

6.2M

13M

BPA

-0.58

Margen de beneficios

-382.531

Empleados

274

EBITDA

789K

-54M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+496.93% upside

Dividendos

By Dow Jones

Próximas Ganancias

15 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-133M

463M

Apertura anterior

7.41

Cierre anterior

4.12

Puntuación técnica

By Trading Central

Confianza

Strong Bearish Evidence

Verve Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

12 may 2025, 22:34 UTC

Adquisiciones, fusiones, absorciones

Ampol to Sell Retail Electricity Businesses in Australia, New Zealand

12 may 2025, 23:48 UTC

Charlas de Mercado

Gold Edges Higher on Possible Technical Recovery -- Market Talk

12 may 2025, 23:46 UTC

Charlas de Mercado

Nikkei Likely to Rise on Hopes for Improving U.S.-China Trade Relations -- Market Talk

12 may 2025, 23:34 UTC

Charlas de Mercado

Trade Deal Lowers US Recession Risks to 35% -- Market Talk

12 may 2025, 23:21 UTC

Charlas de Mercado

US-China Trade Deal Still Risks Stagflation; Supply Chain Disruption -- Market Talk

12 may 2025, 22:54 UTC

Charlas de Mercado

Australian Treasurer Warns Uncertainty Will Still Dominate Markets -- Market Talk

12 may 2025, 22:43 UTC

Ganancias

Telefonica Brasil 1Q EPS BRL0.65 >VIV

12 may 2025, 22:14 UTC

Principales Noticias

Drugmakers Spared Worst-Case Drug Pricing Scenario for Now -- 2nd Update

12 may 2025, 22:08 UTC

Adquisiciones, fusiones, absorciones

Ampol Expects Replacement-Cost Ebitda Uplift by Run Rate at End-2025 of Around A$30 Million/Year

12 may 2025, 22:08 UTC

Adquisiciones, fusiones, absorciones

Ampol Expects Pretax Proceeds of Around A$65 Million From Transactions

12 may 2025, 22:07 UTC

Adquisiciones, fusiones, absorciones

Ampol to Sell Australia Retail Electricity Business for Nominal Sum

12 may 2025, 22:07 UTC

Adquisiciones, fusiones, absorciones

Ampol to Sell Australia Retail Electricity Business to AGL

12 may 2025, 22:06 UTC

Adquisiciones, fusiones, absorciones

Meridian to Take on Flick, Z Energy Branded Electricity Customers

12 may 2025, 22:06 UTC

Adquisiciones, fusiones, absorciones

Meridian Energy to Buy Business From Ampol for NZ$70 Million

12 may 2025, 22:05 UTC

Adquisiciones, fusiones, absorciones

Ampol to Sell New Zealand Electricity Retailing Businesses to Meridian Energy

12 may 2025, 22:04 UTC

Adquisiciones, fusiones, absorciones

Ampol to Sell Retail Electricity Businesses in Australia, New Zealand

12 may 2025, 21:15 UTC

Principales Noticias

Republican Tax Plan Boosts SALT Deduction, Ends Green-Energy Breaks -- 2nd update -- WSJ

12 may 2025, 21:01 UTC

Ganancias

Constellation Software 1Q Rev $2.65B >CSU.T

12 may 2025, 21:01 UTC

Ganancias

Constellation Software 1Q Net $115M >CSU.T

12 may 2025, 21:01 UTC

Ganancias

Constellation Software 1Q EPS $5.44 >CSU.T

12 may 2025, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

12 may 2025, 20:50 UTC

Charlas de Mercado
Ganancias

Basic Materials Roundup: Market Talk

12 may 2025, 20:44 UTC

Principales Noticias

Trade Thaw Sparks Stock Rally, Leaves Wall Street Cautious -- WSJ

12 may 2025, 20:31 UTC

Principales Noticias

How to Think About the Stock Market When Earnings Guidance Becomes Meaningless -- Heard on the Street -- UPDATED -- WSJ

12 may 2025, 20:24 UTC

Ganancias

Energy Vault Holdings: Encouraging News on China/U.S. Tariff Pause, Pending Final Positive Resolution and Timing >NRGV

12 may 2025, 20:24 UTC

Ganancias

Energy Vault Holdings: No Change to Current Guidance, With Potential Rev Upside on Accelerated U.S. Battery Deliveries in 2025 >NRGV

12 may 2025, 20:24 UTC

Principales Noticias

Republican Tax Plan Boosts SALT Deduction, Ends Green-Energy Breaks -- WSJ

12 may 2025, 20:22 UTC

Adquisiciones, fusiones, absorciones

Spirit AeroSystems Holdings: IRS Rules That Sale to Boeing Will Qualify as a Reorganization Under Section 368(a)(1)(B)

12 may 2025, 20:15 UTC

Ganancias

Rigetti Computing Reports Earnings. How the Company Takes a Different Approach to Quantum. -- Barrons.com

12 may 2025, 20:10 UTC

Ganancias

Blink Charging 1Q Rev $20.8M >BLNK

Comparación entre iguales

Cambio de precio

Verve Therapeutics Inc previsión

Precio Objetivo

By TipRanks

496.93% repunte

Estimación a 12 Meses

Media 25.25 USD  496.93%

Máximo 39 USD

Mínimo 15 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Verve Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

10 ratings

9

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

4.1501 / 5.16Soporte y Resistencia

Corto Plazo

Strong Bearish Evidence

Medio plazo

Very Strong Bearish Evidence

Largo Plazo

Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Verve Therapeutics Inc

Verve Therapeutics, Inc., a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH. It engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.